International Cancer Conference Journal最新文献_第2页

Carcinoma esophagus with small bowel metastasis: a case report with review of literature. 食管癌伴小肠转移：病例报告与文献综述。

IF 0.5

International Cancer Conference Journal Pub Date : 2024-08-27 eCollection Date: 2024-10-01 DOI: 10.1007/s13691-024-00717-y

Vigneshwaran Chandran, Kannan Periasamy, Lileswar Kaman, Kirti Gupta, Uma Nahar

{"title":"Carcinoma esophagus with small bowel metastasis: a case report with review of literature.","authors":"Vigneshwaran Chandran, Kannan Periasamy, Lileswar Kaman, Kirti Gupta, Uma Nahar","doi":"10.1007/s13691-024-00717-y","DOIUrl":"https://doi.org/10.1007/s13691-024-00717-y","url":null,"abstract":"Small intestinal metastasis is extremely rare and only 13 cases have been reported till date and almost all such patients have presented with intestinal obstruction. The 5-year overall survival for metastatic esophageal cancer is as low as 5% while the patients with small intestinal metastasis have a median survival of only 3 months (range 1-12 months) despite undergoing radical resection of the small bowel. We present a case of a male in his 50's who presented with difficulty in swallowing for 4 months. On evaluation, he was found to have squamous cell carcinoma in the mid thoracic esophagus. He underwent radical chemo-radiation up to 60 Gy in 25 fractions over 5 weeks. One week after completion of treatment he presented with ileal obstruction and omental nodules and surgical resection and evaluation of the respective ileal segment and omental biopsy revealed a metastatic squamous cell carcinoma. The patient expired 3 months post-surgery. Carcinoma esophagus with small bowel metastasis has a very grave prognosis that patients rarely survive beyond 1 year despite undergoing resection. Hence it is imperative to consider a small bowel metastasis when such patients present with clinical features of intestinal obstruction for early diagnosis and aggressive management.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"13 4","pages":"449-453"},"PeriodicalIF":0.5,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11464811/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Complete response using the EZH2 inhibitor tazemetostat against multiple relapsed follicular lymphoma in the leukemic phase. 使用 EZH2 抑制剂 tazemetostat 治疗处于白血病期的多发性复发滤泡淋巴瘤，获得完全缓解。

IF 0.5

International Cancer Conference Journal Pub Date : 2024-08-21 eCollection Date: 2024-10-01 DOI: 10.1007/s13691-024-00716-z

Shohei Kikuchi, Yoshimi Nabe, Ryusuke Horaguchi, Tomoki Minemura, Jun Murakami, Akira Noguchi, Kohji Takagi, Yusuke Kamihara, Akinori Wada, Takuma Fujihira, Tsutomu Sato

{"title":"Complete response using the EZH2 inhibitor tazemetostat against multiple relapsed follicular lymphoma in the leukemic phase.","authors":"Shohei Kikuchi, Yoshimi Nabe, Ryusuke Horaguchi, Tomoki Minemura, Jun Murakami, Akira Noguchi, Kohji Takagi, Yusuke Kamihara, Akinori Wada, Takuma Fujihira, Tsutomu Sato","doi":"10.1007/s13691-024-00716-z","DOIUrl":"https://doi.org/10.1007/s13691-024-00716-z","url":null,"abstract":"Though multiple relapses and serial shortening of remission is one of the characteristics of follicular lymphoma (FL), standard third- and later-line treatments with clear evidence have not yet been established. Tazemetostat, the first oral enhancer of zester homolog 2 (EZH2) inhibitor, showed a favorable clinical outcome and safety profile against relapsed mutant EZH2 FL in a clinical trial and was applied to this clinical setting. Peripheral blood involvement, known as the leukemic phase, was observed in approximately 10% of patients with FL and reported as a poor prognostic factor. However, because of the infrequency of EZH2-activating mutations, clinical data on tazemetostat against FL in the leukemic phase is lacking. Herein, we report a case of multiple relapsed FL in the leukemic phase for which tazemetostat was administered as a sixth-line treatment. Tazemetostat monotherapy showed a slow and sustained clinical efficacy in the leukemic phase as shown by nodal involvement. Circulating lymphoma cells gradually decreased and disappeared in counts after 4 months of treatment. However, circulating lymphoma cells were still detected by flow cytometry up to 6 months of treatment and finally undetected after 9 months. Extended-interval dosing of tazemetostat transformed a partial response into a complete response. Thus, tazemetostat is effective for the treatment of multiple relapsed FL in the leukemic phase.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"13 4","pages":"488-492"},"PeriodicalIF":0.5,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11465062/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Radiation hepatitis after postmastectomy radiation therapy for early breast cancer: difficult to differentiate from drug-induced liver injury caused by abemaciclib. 早期乳腺癌乳房切除术后放射治疗后的放射性肝炎：难以与阿贝昔单抗导致的药物性肝损伤区分开来。

IF 0.5

International Cancer Conference Journal Pub Date : 2024-08-19 eCollection Date: 2024-10-01 DOI: 10.1007/s13691-024-00714-1

Shogo Nakamoto, Takahiro Waki, Asuka Mimata, Takahiro Tsukioki, Yuko Takahashi, Yoko Iwatani, Tsuguo Iwatani, Tadahiko Shien

{"title":"Radiation hepatitis after postmastectomy radiation therapy for early breast cancer: difficult to differentiate from drug-induced liver injury caused by abemaciclib.","authors":"Shogo Nakamoto, Takahiro Waki, Asuka Mimata, Takahiro Tsukioki, Yuko Takahashi, Yoko Iwatani, Tsuguo Iwatani, Tadahiko Shien","doi":"10.1007/s13691-024-00714-1","DOIUrl":"https://doi.org/10.1007/s13691-024-00714-1","url":null,"abstract":"Abemaciclib (ABM) is recommended for adjuvant endocrine therapy in hormone receptor-positive, human epidermal growth factor receptor type 2-negative early breast cancer (EBC) patients at high risk of recurrence. Here, we present a case of radiation hepatitis challenging to differentiate from drug-induced liver injury during ABM treatment. The patient, a woman in her 40 s, underwent right mastectomy, axillary dissection, and postmastectomy radiation therapy (PMRT) after neoadjuvant chemotherapy for EBC. Subsequently, she received ABM as adjuvant endocrine therapy. Despite suspending ABM due to Grade 3 leukopenia, she developed Grade 3 hepatic dysfunction upon cessation. Based on the dynamic contrast-enhanced computed tomography, we diagnosed the cause of liver dysfunction as radiation hepatitis. Spontaneous improvement allowed us to resume ABM treatment. Clinicians may need to consider radiation hepatitis as a potential cause of hepatic dysfunction in patients who underwent PMRT, along with drug-induced liver injury.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"13 4","pages":"471-475"},"PeriodicalIF":0.5,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11464992/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fertility preservation in men with hypogonadotropic hypogonadism secondary to germinoma: two cases of gonadotropin replacement therapy before induction of anticancer chemotherapy. 生殖细胞瘤继发性性腺功能减退症男性的生育力保护：两例在诱导抗癌化疗前进行促性腺激素替代治疗的病例。

IF 0.5

International Cancer Conference Journal Pub Date : 2024-08-16 eCollection Date: 2024-10-01 DOI: 10.1007/s13691-024-00711-4

Yasuhiro Kaku, Koji Chiba, Yosuke Yamashita, Shun Kawamura, Katsuya Sato, Takuto Hara, Keisuke Okada, Hideaki Miyake

{"title":"Fertility preservation in men with hypogonadotropic hypogonadism secondary to germinoma: two cases of gonadotropin replacement therapy before induction of anticancer chemotherapy.","authors":"Yasuhiro Kaku, Koji Chiba, Yosuke Yamashita, Shun Kawamura, Katsuya Sato, Takuto Hara, Keisuke Okada, Hideaki Miyake","doi":"10.1007/s13691-024-00711-4","DOIUrl":"https://doi.org/10.1007/s13691-024-00711-4","url":null,"abstract":"Hypogonadotropic hypogonadism can be caused by brain tumors. For a malignancy such as a germ cell tumor, chemotherapy combined with radiation is administered. In patients who wish for children, the inability to undergo sperm cryopreservation before treatment because of impaired spermatogenesis and/or ejaculation dysfunction can be problematic. We herein present two cases involving a 26-year-old man and a 30-year-old man with hypogonadotropic hypogonadism due to an intracranial germinoma and both wished to have children. Gonadotropin replacement therapy prior to anticancer chemotherapy resulted in subsequent spontaneous pregnancy or assisted reproductive therapy. Subsequent treatment of the tumor resulted in no recurrence for 9 and 2 years, respectively. Close consultation with an oncologist is mandatory in such cases. Depending on the tumor prognosis, however, it may be possible to delay tumor treatment and prioritize fertility because there is a possibility of impaired spermatogenesis due to additional chemotherapy.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"13 4","pages":"468-470"},"PeriodicalIF":0.5,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11464966/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

High likelihood of BRCA2 reversion mutation in pancreatic cancer post-platinum-based chemotherapy: a case study. 铂类化疗后胰腺癌 BRCA2 发生逆转突变的可能性很高：一项病例研究。

IF 0.5

International Cancer Conference Journal Pub Date : 2024-08-16 eCollection Date: 2024-10-01 DOI: 10.1007/s13691-024-00715-0

Taro Hanaoka, Kosuke Okuwaki, Kohei Nakamura, Shunji Okada, Nobuyuki Nishizawa, Masafumi Watanabe, Tomohisa Iwai, Kai Adachi, Yusuke Kumamoto, Chika Kusano

{"title":"High likelihood of BRCA2 reversion mutation in pancreatic cancer post-platinum-based chemotherapy: a case study.","authors":"Taro Hanaoka, Kosuke Okuwaki, Kohei Nakamura, Shunji Okada, Nobuyuki Nishizawa, Masafumi Watanabe, Tomohisa Iwai, Kai Adachi, Yusuke Kumamoto, Chika Kusano","doi":"10.1007/s13691-024-00715-0","DOIUrl":"https://doi.org/10.1007/s13691-024-00715-0","url":null,"abstract":"A 54-year-old man with resectable pancreatic cancer and abnormally high levels of carbohydrate antigen 19-9 (CA19-9) underwent 6 months of platinum-based chemotherapy. This treatment substantially reduced the primary tumor size and normalized CA19-9 levels. Subsequently, radical surgery was conducted. However, eight months post-surgery, CA19-9 levels re-elevated, and lymph-node recurrence was observed. The patient underwent treatment with poly(adenosine diphosphate ribose) polymerase inhibitors (PARPi) following the detection of frameshift L1904fs*5 via BRACAnalysis CDx. This mutation revealed a stop codon, leading to the inactivation of the BRCA function. Additionally, the patient tested positive for a mutation in the breast cancer susceptibility gene 2 (BRCA2). Two months after starting PARPi, there was evidence of tumor shrinkage. Nevertheless, 5 months later, CA19-9 levels increased again, and new metastatic tumors in the liver were identified. Genomic profiling test (FoundationOne CDx) of surgically resected specimens revealed a BRCA2 pL1908fs*2 mutation, indicating its location in the cis position on the same allele as the germline BRCA2 mutation. The pL1908fs*2 deletion, alongside the original L1904fs*5, resulted in three deletions, equating to one amino acid deletion. This deletion ultimately reversed the stop codon, leading to the restoration of BRCA2 functionality. Despite treatment with PARPi for postoperative recurrence, a sustained response was not achieved owing to BRCA reversion mutations. It is essential to acknowledge the rarity of BRCA reversion mutations, which limit the effectiveness of PARPi.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"13 4","pages":"493-498"},"PeriodicalIF":0.5,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11464854/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Breast mucoepidermoid carcinoma with a rare CRTC3-MAML2 fusion. 乳腺粘液表皮样癌伴有罕见的 CRTC3-MAML2 融合。

IF 0.5

International Cancer Conference Journal Pub Date : 2024-08-12 eCollection Date: 2024-10-01 DOI: 10.1007/s13691-024-00713-2

Kana Kawaguchi, Hideki Ijichi, Hiroki Ueo, Yuichi Hisamatsu, Sachie Omori, Tomoko Shigechi, Kengo Kawaguchi, Hidetaka Yamamoto, Yoshinao Oda, Makoto Kubo, Tomoharu Yoshizumi

{"title":"Breast mucoepidermoid carcinoma with a rare CRTC3-MAML2 fusion.","authors":"Kana Kawaguchi, Hideki Ijichi, Hiroki Ueo, Yuichi Hisamatsu, Sachie Omori, Tomoko Shigechi, Kengo Kawaguchi, Hidetaka Yamamoto, Yoshinao Oda, Makoto Kubo, Tomoharu Yoshizumi","doi":"10.1007/s13691-024-00713-2","DOIUrl":"https://doi.org/10.1007/s13691-024-00713-2","url":null,"abstract":"Mucoepidermoid carcinoma is the most prevalent malignancy in the salivary gland and is sporadic in the breast. Here, we report a case of breast mucoepidermoid carcinoma with a rare CREB-regulated transcription coactivator 3-mastermind-like transcriptional coactivator 2 (CRTC3-MAML2) fusion. A 23-year-old female was admitted to our hospital with a left breast palpable mass. Histologic findings of the core-needle biopsy indicated breast cancer. The section revealed a squamoid tumor-cell proliferation with enlarged nuclei and eosinophilic cytoplasm among smaller intermediate cells and abundant cystic spaces containing secretory materials. The features were compatible with mucoepidermoid carcinoma in low-grade, confirmed by detecting the CRTC3-MAML2 fusion using reverse transcription polymerase chain reaction and direct sequencing. We only administered tamoxifen postoperatively without other adjuvant therapy because her tumor partially expressed hormonal receptors. No signs indicate a recurrence or metastasis in our over 3 year follow-up. The genetic analysis helps in definitively diagnosing breast mucoepidermoid carcinoma, and the treatment strategy should be considered based on the histologic findings.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"13 4","pages":"481-487"},"PeriodicalIF":0.5,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11464662/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cerebral arterial air embolism after esophageal stenting for recurrence of gastroesophageal junction cancer: a case report. 食管支架术治疗胃食管交界处癌症复发后的脑动脉空气栓塞：病例报告。

IF 0.5

International Cancer Conference Journal Pub Date : 2024-08-06 eCollection Date: 2024-10-01 DOI: 10.1007/s13691-024-00710-5

Susumu Saigusa, Yuki Aono, Hiroyuki Fujikawa, Ryo Uratani, Shuyo Watanabe, Hiroyuki Sakurai, Masaki Ohi, Koji Tanaka

{"title":"Cerebral arterial air embolism after esophageal stenting for recurrence of gastroesophageal junction cancer: a case report.","authors":"Susumu Saigusa, Yuki Aono, Hiroyuki Fujikawa, Ryo Uratani, Shuyo Watanabe, Hiroyuki Sakurai, Masaki Ohi, Koji Tanaka","doi":"10.1007/s13691-024-00710-5","DOIUrl":"https://doi.org/10.1007/s13691-024-00710-5","url":null,"abstract":"Cerebral arterial air embolism (CAE) is a rare complication after esophageal stenting, but it can be life-threatening. It is especially a concern for those with a history of previous gastrointestinal cancer therapies. We report a case of CAE after esophageal stenting in a patient with recurrent gastroesophageal junction cancer and a history of multiple cancer treatments. A 71 year-old man with a history of a proximal gastrectomy, resection of the lower esophagus, chemotherapy, and radiation presented to our hospital 2 weeks after stenting with epigastric and back pain. Mediastinitis was suspected and conservative treatment was begun. The patient suddenly developed altered mental status, left hemiplegia, and anisocoria after drinking water. A brain computed tomography (CT) revealed right-sided predominance of multifocal CAE. Chest and abdominal CT showed a hematoma in the gastric and duodenal wall and an intraluminal hematoma from the esophagus, around the stent, to the upper ileum. CAE was thought to be due to rupture of the recurrent tumor. Unfortunately, despite intensive care, the patient died about 5 h after the onset of neurological symptoms. It has been reported that prior treatments, such as chemotherapy and radiotherapy, increase the risk of life-threatening adverse events, including CAE after esophageal stenting. Clinicians should keep in mind the possibility of CAE after esophageal stenting in patients with a history of multiple cancer treatments.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"13 4","pages":"460-467"},"PeriodicalIF":0.5,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11464815/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Primary mediastinal choriocarcinoma in a woman treated with VIP therapy instead of BEP therapy for the prevention of postoperative acute respiratory distress syndrome. 为预防术后急性呼吸窘迫综合征，一名妇女接受了VIP疗法而非BEP疗法治疗，结果患上了原发性纵隔绒毛膜癌。

IF 0.5

International Cancer Conference Journal Pub Date : 2024-08-05 eCollection Date: 2024-10-01 DOI: 10.1007/s13691-024-00708-z

Yuka Aida, Ryo Watanabe, Kensuke Nakazawa, Naohiro Kobayashi, Takashi Kawahara, Hitomi Kawai, Ikuo Sekine, Nobuyuki Hizawa

{"title":"Primary mediastinal choriocarcinoma in a woman treated with VIP therapy instead of BEP therapy for the prevention of postoperative acute respiratory distress syndrome.","authors":"Yuka Aida, Ryo Watanabe, Kensuke Nakazawa, Naohiro Kobayashi, Takashi Kawahara, Hitomi Kawai, Ikuo Sekine, Nobuyuki Hizawa","doi":"10.1007/s13691-024-00708-z","DOIUrl":"https://doi.org/10.1007/s13691-024-00708-z","url":null,"abstract":"Primary mediastinal germ cell tumor (PMGCT) is an extragonadal germ cell tumor (GCT) that is classified as a poor-prognosis subtype among GCTs. Among them, choriocarcinoma accounts for 2% and its prognosis is considered to be notably poor. The standard treatment for advanced germ cell tumors is BEP therapy (bleomycin, etoposide, cisplatin), followed by surgical resection. However, treatments containing bleomycin are associated with postoperative acute respiratory distress syndrome (ARDS). We report a 38-year-old woman with locally advanced primary mediastinal choriocarcinoma. A computed tomography (CT) of the chest showed a 6.5 cm solid mass in the anterior mediastinum that had invaded the superior vena cava. Laboratory data revealed a serum total human chorionic gonadotropin (hCG) value of 298,220 mIU/mL. After one course of BEP therapy, her total hCG level decreased markedly, and the patient was switched to VIP therapy (etoposide, ifosfamide, cisplatin), a bleomycin-free regimen, to reduce the risk of ARDS. Three courses of VIP therapy and one course of salvage therapy enabled a complete surgical resection without any complications including ARDS. The patient has been disease-free for 16 months since the resection.Supplementary information: The online version contains supplementary material available at 10.1007/s13691-024-00708-z.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"13 4","pages":"445-448"},"PeriodicalIF":0.5,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11464724/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of HER2-positive and microsatellite instability-high advanced gastric cancer: a case report. HER2阳性、微卫星不稳定性高的晚期胃癌的治疗：病例报告。

IF 0.5

International Cancer Conference Journal Pub Date : 2024-08-02 eCollection Date: 2024-10-01 DOI: 10.1007/s13691-024-00707-0

Taichi Tamura, Yusuke Kanemasa, Shohei Nakamura, Toshihiro Okuya, Yu Yagi, Shinichiro Matsuda, Mitsutaka Murata, Kazuya Endo, Kentaro Hara, Hiroko Okinaga, Shin-Ichiro Horiguchi, Yasuji Seyama, Haruhiko Cho, Tatsu Shimoyama

{"title":"Management of HER2-positive and microsatellite instability-high advanced gastric cancer: a case report.","authors":"Taichi Tamura, Yusuke Kanemasa, Shohei Nakamura, Toshihiro Okuya, Yu Yagi, Shinichiro Matsuda, Mitsutaka Murata, Kazuya Endo, Kentaro Hara, Hiroko Okinaga, Shin-Ichiro Horiguchi, Yasuji Seyama, Haruhiko Cho, Tatsu Shimoyama","doi":"10.1007/s13691-024-00707-0","DOIUrl":"https://doi.org/10.1007/s13691-024-00707-0","url":null,"abstract":"Chemotherapy for advanced gastric cancer has progressed significantly in the past few decades. Biomarker-specific drugs, including anti-human epidermal growth factor receptor 2 (HER2) drugs for HER2-positive patients and immune checkpoint inhibitors for those with microsatellite instability-high (MSI-H), have become common. However, patients who are positive for HER2 and have MSI-H are extremely rare, and there are no established treatments for these patients. We present the case of a 75-year-old, male patient with gastric cancer with lymph node metastases and liver infiltration. Biomarker analysis revealed HER2 3 + , loss of MLH1, and MSI-H. After three cycles of S-1, oxaliplatin, and trastuzumab, the primary tumor and metastases shrank markedly. He subsequently underwent gastrectomy and hepatectomy as conversion surgery, achieving a pathologically complete response. He has been recurrence-free for seven months postoperatively. The present case demonstrated the efficacy of trastuzumab-containing chemotherapy followed by conversion surgery in a patient with HER2-positive, MSI-H, advanced gastric cancer.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"13 4","pages":"342-347"},"PeriodicalIF":0.5,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11464906/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Synchronous gastric and ovarian cancer successfully treated with FOLFOX therapy: a case report and review of the literature. FOLFOX疗法成功治疗同步性胃癌和卵巢癌：病例报告和文献综述。

IF 0.5

International Cancer Conference Journal Pub Date : 2024-08-01 eCollection Date: 2024-10-01 DOI: 10.1007/s13691-024-00704-3

Makiko So, Aya Shimoji, Yoko Iemura, Ai Suizu, Shuichiro Iwami, Masahito Hoki, Shinsuke Shibuya

{"title":"Synchronous gastric and ovarian cancer successfully treated with FOLFOX therapy: a case report and review of the literature.","authors":"Makiko So, Aya Shimoji, Yoko Iemura, Ai Suizu, Shuichiro Iwami, Masahito Hoki, Shinsuke Shibuya","doi":"10.1007/s13691-024-00704-3","DOIUrl":"https://doi.org/10.1007/s13691-024-00704-3","url":null,"abstract":"Synchronous gastric and ovarian cancer is extremely rare, and there have been no case reports. Here, we present the first case of synchronous gastric and ovarian cancer successfully treated with chemotherapy and surgery. A 72-year-old Japanese woman presented at our hospital with upper abdominal pain and vomiting. She was diagnosed with gastric cancer after undergoing upper gastrointestinal endoscopy. Simultaneously, ovarian cancer was also suspected based on imaging studies which showed a 9 cm cystic lesion with a solid part on the right ovary. Since her gastric cancer was considered inoperable due to the extent of the lesion, she was treated with four courses of oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX therapy). Since both gastric and ovarian cancer lesions were found to be reduced in size, laparoscopic total gastrectomy (D1 dissection, with Roux-en-Y reconstruction), bilateral adnexectomy, and partial omentectomy were performed. Based on pathological and immunohistochemical findings, the diagnosis of synchronous cancer of poorly differentiated carcinoma of the stomach and endometrioid carcinoma of the ovary was made, and it became clear that FOLFOX therapy was effective especially against ovarian cancer. The patient is currently undergoing postoperative chemotherapy with FOLFOX + nivolumab. She remains alive 8 months after surgery, with no active lesions. This is the first report of a patient with synchronous gastric and ovarian cancer, suggesting that FOLFOX therapy may be effective as a first-line treatment of endometrioid carcinoma of the ovary.","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"13 4","pages":"427-432"},"PeriodicalIF":0.5,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11465018/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142464421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0